Scarica l'app Stockscreener
4.95
9.60%
-0.49
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CAMP Giù?
Forum
Previsione
Frazionamento azionario
Camp 4 Therapeutics Corp Borsa (CAMP) Ultime notizie
ETFs Investing in CAMP4 Therapeutics Corporation Stocks - TradingView
Balyasny group discloses 4.99% Camp4 Therapeutics (CAMP) position with warrant blocker - Stock Titan
CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
CAMP4 Q2 Loss Widens to $33.5M; EPS Misses Estimates - scanx.trade
CAMP4 Therapeutics (Nasdaq: CAMP) widens loss as derivative liability surges - Stock Titan
CAMP4 Therapeutics (CAMP) widens Q2 2026 loss, boosts cash runway to 2028 - Stock Titan
CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights - The Manila Times
Camp4 Therapeutics Corp SEC Filing (Aug 13, 2026) - Stock Titan
CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Given Average Recommendation of "Moderate Buy" by Analysts - marketbeat.com
Trails Edge reports 6% Camp4 Therapeutics stake (CAMP) totaling 3.79M shares - Stock Titan
CAMP4 Therapeutics Corp expected to post a loss of 21 cents a shareEarnings Preview - TradingView
Camp4 Therapeutics Corp CEO to launch new SYNGAP1 clinical trial in upcoming initiative - tradersunion.com
Yuri Maricich Acquires 6,551 Shares of CAMP4 Therapeutics (NASDAQ:CAMP) Stock - MarketBeat
CAMP4 Therapeutics (NASDAQ:CAMP) CEO Josh Mandel-Brehm Purchases 6,551 Shares - MarketBeat
Richard Young Buys 16,378 Shares of CAMP4 Therapeutics (NASDAQ:CAMP) Stock - marketbeat.com
Insider Buying: CAMP4 Therapeutics (NASDAQ:CAMP) CFO Buys $10,809.15 in Stock - marketbeat.com
5AM Ventures group updates CAMP4 Therapeutics (CAMP) stake and warrant terms - Stock Titan
CAMP4 closes $50.1 million second tranche of private placement By Investing.com - Investing.com India
CAMP4 Therapeutics Secures $50 Million Private Financing - TipRanks
Camp4 Therapeutics Raises $50.1 Million in Second Closing of Private Placement - TradingView
CAMP4 Therapeutics (Nasdaq: CAMP) raises $50.1M in second private placement closing - Stock Titan
CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement - GlobeNewswire
Camp4 Therapeutics Corp leverages regulatory RNA to target genetic root causes - Traders Union
SummitTX Capital L.P. Invests $1.50 Million in CAMP4 Therapeutics Corporation $CAMP - marketbeat.com
CAMP4 Therapeutics Corporation Revenue Breakdown – NASDAQ:CAMP - TradingView
CAMP4 THERAPEUTICS CORPORATION (CAMP) Stock Forecasts - Yahoo! Finance Canada
Analysts Are Bullish on These NA Stocks: SpaceX (SPCX), CAMP4 Therapeutics Corporation (CAMP) - The Globe and Mail
Camp4 Moves Into Human Trials -- The Upside Is Underpriced (NASDAQ:CAMP) - Seeking Alpha
CAMP4 receives Australian clearance for SYNGAP1 therapy trial By Investing.com - Investing.com UK
CAMP4 THERAPEUTICS CORPORATION (CAMP) stock price, news, quote and history - Yahoo Finance UK
Camp4 Therapeutics’ lead ASO approved for clinical trials in Australia - BioWorld News
CAMP4 receives Australian clearance for SYNGAP1 therapy trial - Investing.com Australia
Camp4 Therapeutics Corp secures clinical trial approval for first SYNGAP1 disease-modifying therapy in Australia - Traders Union
CAMP4 Therapeutics (CAMP) clears CMP-002 trial in Australia, eyes $50.1M raise - Stock Titan
CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder - globenewswire.com
CAMP4 Therapeutics Corp (CAMP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CAMP4 Therapeutics Corp (CAMP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CAMP|CAMP4 Therapeutics Corp|Price:3.440|Chg%:+0.280 - TradingKey
Camp4 Therapeutics secures TGA clearance for CMP-002, enabling up to $50.1M second closing - TradingView
CAMP|CAMP4 Therapeutics Corp|Price:3.160|Chg%:+0.150 - TradingKey
CAMP4 Therapeutics Corp (CAMP) Cash Flow - TradingKey
TradingKey - TradingKey
CAMP4 Therapeutics Corp (CAMP) Income Statement - TradingKey
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Here's Why We're Not Too Worried About Camp4 Therapeutics' (NASDAQ:CAMP) Cash Burn Situation - Moomoo
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
We Think Camp4 Therapeutics (NASDAQ:CAMP) Can Afford To Drive Business Growth - Sahm
New strong sell stocks for July 16th - MSN
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
CAMP4 Therapeutics grants inducement stock options to new employee - scanx.trade
New Strong Sell Stocks for July 16th - The Globe and Mail
CAMP News | CAMP4 THERAPEUTICS CORP (NASDAQ:CAMP) - ChartMill
CAMP Q1 2026 Earnings: EPS Surprise Misses Estimates as Company Navigates Early-Stage Pipeline - dars.gov.et
CAMP Q1 2026 Earnings: Wider-Than-Expected Loss Despite 2% Stock UptickEarnings Seasonality - dars.gov.et
Is CAMP4 THERAPEUTICS CORPORATION (CAMP) Stock Undervalued Ahead of Key CMP-002 Clinical Development Milestones? - Yahoo Finance
X4 Pharmaceuticals appoints Kelly Gold to board of directors - Investing.com UK
X4 Pharmaceuticals appoints Kelly Gold to board of directors By Investing.com - Investing.com India
Kelly Gold joins X4 Pharmaceuticals (Nasdaq: XFOR) board and Audit Committee - Stock Titan
Camp4 Therapeutics Corporation(NasdaqGM: CAMP) added to Russell 2000 Index - marketscreener.com
Camp4 Therapeutics Corporation(NasdaqGM:CAMP) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Camp4 Therapeutics Corporation(NasdaqGM:CAMP) added to Russell 2000 Growth Benchmark - marketscreener.com
Camp4 Therapeutics Corporation(NasdaqGM:CAMP) added to Russell 3000E Growth Benchmark - marketscreener.com
Enterprise value to EBITDA forward of CAMP4 Therapeutics Corporation – NASDAQ:CAMP - TradingView
Enterprise value to EBITDA forward of CAMP4 Therapeutics Corporation – BOATS:CAMP - TradingView
Camp4 Therapeutics Corporation(NasdaqGM: CAMP) added to Russell 3000 Index - marketscreener.com
Enterprise value to EBIT forward of CAMP4 Therapeutics Corporation – NASDAQ:CAMP - TradingView
Enterprise value to revenue forward of CAMP4 Therapeutics Corporation – NASDAQ:CAMP - TradingView
2.83%
2.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):